| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0020-7292(12)60025-3 |
| P698 | PubMed publication ID | 22999503 |
| P2093 | author name string | Michael Friedlander | |
| Christopher Crum | |||
| Jonathan S Berek | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction | Q74519481 | ||
| Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer | Q80423982 | ||
| ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT) | Q81738925 | ||
| Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial | Q84574337 | ||
| Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial | Q95790424 | ||
| ARID1A mutations in endometriosis-associated ovarian carcinomas | Q24610484 | ||
| Effect of Screening on Ovarian Cancer Mortality | Q26253810 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews | Q29619407 | ||
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group | Q31962966 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors | Q33366040 | ||
| Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 | ||
| Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study | Q33501657 | ||
| Calculator for ovarian carcinoma subtype prediction | Q33763357 | ||
| Granulosa cell tumor of the ovary | Q33964934 | ||
| Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials | Q34027970 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. | Q34181986 | ||
| The distal fallopian tube: a new model for pelvic serous carcinogenesis. | Q34601152 | ||
| Classification of human ovarian tumors | Q34660680 | ||
| Long-term follow-up of women with ovarian cancer after positive second-look laparotomy | Q35607770 | ||
| Presenting symptoms of epithelial ovarian cancer | Q36132684 | ||
| Symptoms associated with diagnosis of ovarian cancer: a systematic review | Q36164031 | ||
| Management of platinum-sensitive recurrent ovarian cancer | Q36485320 | ||
| Chemotherapy for advanced germ cell tumors | Q36678627 | ||
| The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer | Q36714706 | ||
| A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites | Q36804792 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors | Q36830657 | ||
| Management of ovarian stromal cell tumors | Q36873080 | ||
| Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction | Q36924865 | ||
| New insights into the pathogenesis of serous ovarian cancer and its clinical impact | Q37119411 | ||
| Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention | Q37125079 | ||
| Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis | Q37276915 | ||
| Lymph node-positive stage IIIC ovarian cancer: a separate entity? | Q37643310 | ||
| Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin | Q37649484 | ||
| Current update on borderline ovarian neoplasms. | Q37679522 | ||
| Testicular germ cell tumors: pathogenesis, diagnosis and treatment | Q37813398 | ||
| Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. | Q37893423 | ||
| Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study | Q37954582 | ||
| Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group | Q38471469 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Dysgerminoma: the role of conservative surgery | Q40919856 | ||
| Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma | Q40933444 | ||
| Surveillance policy for stage I ovarian germ cell tumors | Q41366814 | ||
| Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience | Q41477469 | ||
| Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu | Q42905560 | ||
| Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan | Q43675453 | ||
| Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada | Q44116893 | ||
| Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study | Q44145129 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study | Q45237716 | ||
| Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial | Q46221067 | ||
| Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer | Q46445233 | ||
| Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. | Q46584149 | ||
| Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula | Q46591714 | ||
| Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria | Q47799946 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer | Q50512108 | ||
| Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer | Q50771638 | ||
| Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | Q51301047 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. | Q53298016 | ||
| Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. | Q53337533 | ||
| Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. | Q53341537 | ||
| A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. | Q53558960 | ||
| The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. | Q53639283 | ||
| Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group | Q56533522 | ||
| Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel | Q57265736 | ||
| Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer | Q57562304 | ||
| Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma | Q60685709 | ||
| Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial | Q61900008 | ||
| Carcinoma of the fallopian tube | Q64049447 | ||
| Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma. | Q64967159 | ||
| Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin | Q67655336 | ||
| Treatment of malignant ovarian germ cell tumors with preservation of fertility: A report of 28 cases | Q67912503 | ||
| Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer | Q70128564 | ||
| Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience | Q72361846 | ||
| Oral etoposide is active against platinum-resistant epithelial ovarian cancer | Q72681506 | ||
| Paclitaxel-based chemotherapy in carcinoma of the fallopian tube | Q73341701 | ||
| Survival and reproductive function after treatment of malignant germ cell ovarian tumors | Q73446789 | ||
| A genetic epidemiological study of carcinoma of the fallopian tube | Q73661792 | ||
| Conservative surgery for stage I ovarian carcinoma in women of childbearing age | Q73723517 | ||
| Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study | Q73881576 | ||
| P921 | main subject | uterine tube | Q1233836 |
| P304 | page(s) | S118-29 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | International Journal of Gynecology and Obstetrics | Q15746544 |
| P1476 | title | Cancer of the ovary, fallopian tube, and peritoneum | |
| P478 | volume | 119 Suppl 2 |
| Q36860111 | A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression |
| Q58704303 | A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report |
| Q57164774 | A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study |
| Q40257441 | An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: a case report |
| Q53499541 | Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. |
| Q87714163 | Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? |
| Q37392946 | Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. |
| Q34241202 | Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer |
| Q37604669 | Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). |
| Q28081482 | Fertility sparing treatment in borderline ovarian tumours |
| Q92839824 | High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women |
| Q33779282 | Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers |
| Q37597335 | Management of borderline ovarian tumours: a comprehensive review of the literature. |
| Q33609359 | MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma |
| Q37114974 | MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12. |
| Q91813983 | Ovarian Cancer Dissemination-A Cell Biologist's Perspective |
| Q36032691 | Ovarian cancer survival by tumor dominance, a surrogate for site of origin |
| Q36023938 | Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q35902265 | Primary fallopian tube carcinoma: review of MR imaging findings |
| Q26751280 | Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives |
| Q35941858 | RETRACTED ARTICLE: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer |
| Q37553978 | Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management |
| Q38330192 | Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review. |
| Q45064784 | Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer |
| Q52571294 | Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas. |
| Q38140533 | The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part I--Omental function and history of omentectomy |
| Q58755561 | The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer |
| Q92967864 | The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma |
| Q46249083 | Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria |
| Q36685324 | YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. |
Search more.